• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALCON RESEARCH, LLC - HUNTINGTON ACRYSOF IQ VIVITY EXTENDED VISION IOL; INTRAOCULAR LENS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALCON RESEARCH, LLC - HUNTINGTON ACRYSOF IQ VIVITY EXTENDED VISION IOL; INTRAOCULAR LENS Back to Search Results
Model Number DFT015
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Halo (2227); Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available (4581)
Type of Reportable Event Serious Injury
Event or Problem Description
A consumer reported that following a cataract extraction with intraocular lens (iol) implant procedure, consumer experienced halos around light during day and night.But following posterior capsular opacification, the halos disappeared 80% during the day and 50% at night.The symptoms started 2 months after surgery.The surgeon was prescribed with pilocarpine to decrease the symptoms.No further information available.There are two medical device reports associated with this patient.This report is associated with the left eye.
 
Additional Manufacturer Narrative
A sample device was not returned for analysis.Complaint history and product history records were reviewed and documentation indicated the product met release criteria.Root cause has not been identified.There have been no other complaints reported in the lot number.The manufacturer internal reference number is: (b)(4).
 
Additional Manufacturer Narrative
The lens remains implanted.Information was provided in the follow up that halos around all light for both eyes started about two months after surgery in both eyes, day and night, no difference.Following posterior capsular opacification, the halos disappeared 80% during the day and 50% at night.Patient discussed with surgeon, and prognosis is that halos would not disappear.Surgeon prescribed isopt carpine 2% to decrease symptoms with no change.The manufacturer internal reference number is: (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ACRYSOF IQ VIVITY EXTENDED VISION IOL
Common Device Name
INTRAOCULAR LENS
Manufacturer (Section D)
ALCON RESEARCH, LLC - HUNTINGTON
6065 kyle lane
huntington WV 25702
Manufacturer (Section G)
ALCON RESEARCH, LLC - HUNTINGTON
6065 kyle lane
huntington WV 25702
Manufacturer Contact
jonathan schlech
6201 south freeway
mail stop ab2-6
fort worth, TX 76134
8007579780
MDR Report Key15250724
Report Number1119421-2022-01800
Device Sequence Number6612553
Product Code POE
UDI-Device Identifier00380652421171
UDI-Public00380652421171
Combination Product (Y/N)N
Initial Reporter CountryCA
PMA/510(K) Number
P930014
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2021
Reporter Type Manufacturer
Report Source Foreign,Consumer
Initial Reporter Occupation Non-Healthcare Professional
Type of Report Initial,Followup
Report Date (Section B) 11/22/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date08/06/2025
Device Model NumberDFT015
Device Lot Number15086383
Was Device Available for Evaluation? No
Type of Report(Section G)Initial
Initial Date Received by Manufacturer 07/25/2022
Supplement Date Received by Manufacturer10/25/2022
Initial Report FDA Received Date08/18/2022
Supplement Report FDA Received Date11/22/2022
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured08/07/2020
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
ISOPTO CARPINE 2%
Outcome Attributed to Adverse Event Required Intervention;
Patient Age69 YR
Patient SexMale
-
-